BRIEF-Travere Therapeutics Announces FDA Acceptance Of SNDA For FILSPARI® (Sparsentan) In FSGS

Reuters
16 May
BRIEF-Travere <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces FDA Acceptance Of SNDA For FILSPARI® (Sparsentan) In FSGS

May 15 (Reuters) - Travere Therapeutics Inc TVTX.O:

  • TRAVERE THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF SNDA FOR FILSPARI® (SPARSENTAN) IN FSGS

  • TRAVERE THERAPEUTICS INC - PDUFA TARGET ACTION DATE SET FOR JANUARY 13, 2026

  • TRAVERE THERAPEUTICS INC - FILSPARI COULD BE FIRST FDA-APPROVED TREATMENT FOR FSGS

Source text: ID:nBw3cJ84da

Further company coverage: TVTX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10